Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323447 | 1.00 | CFTR (0.38) | CFTRADORA2AADORA1NLRP3GAA | |
| SCHEMBL10324942 | 1.00 | CFTR (0.38) | CFTRADORA2AADORA1NLRP3GAA | |
| SCHEMBL28109304 | 0.94 | GAA (0.37) | CFTRADORA2AADORA1NLRP3GAA | |
| SCHEMBL22041388 | 0.82 | CFTR (0.38) | CFTRADORA2AADORA1NLRP3GAA | |
| SCHEMBL23579143 | 0.78 | ADORA2A (0.35) | CFTRADORA2AADORA1GAASMN1; SMN2 | |
| SCHEMBL10442292 | 0.77 | TSHR (0.46) | SMN1; SMN2CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL2557814 | 0.77 | MEN1 (0.44) | NLRP3GAASMN1; SMN2PDE10ACYP3A4 | |
| SCHEMBL29151150 | 0.77 | GAA (0.40) | NLRP3GAAPKM | |
| SCHEMBL27405786 | 0.77 | HTR2C (0.43) | NLRP3GAASMN1; SMN2KDM4EMAPT | |
| SCHEMBL27997001 | 0.77 | PKM (0.36) | ADORA2AADORA1NLRP3GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9572809-B2 | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572809-B2 | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012097269-A1 | PYRIMIDINE GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | CFTR 179/4885ADORA2A 4566/4885ADORA1 4073/4885 |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | CFTR 798/4885ADORA2A 4684/4885ADORA1 3877/4885 |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | CFTR 424/4885ADORA2A 4715/4885ADORA1 4197/4885 |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | CFTR 755/4885ADORA2A 4496/4885ADORA1 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.